API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Apollomics intends to use the net proceeds to fund its pipeline programs including, APL-101 (vebreltinib), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations.
Lead Product(s): Vebreltinib
Therapeutic Area: Oncology Product Name: APL-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Canaccord Genuity
Deal Size: $6.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement May 08, 2024
Details:
APL-101 (vebreltinib) is a highly specific cMet inhibitor which is indicated for the treatment of sGBM/IDH mutant glioblastoma with the ZM fusion gene.
Lead Product(s): Vebreltinib
Therapeutic Area: Oncology Product Name: PLB1001
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 25, 2024
Details:
The collaboration aims to advance the development of PredicineCARE, a blood cfDNA NGS assay, to identify NSCLC patients who may benefit from targeted therapy, APL-101 (vebreltinib), a novel, potent, selective and orally bioavailable small molecule c-Met inhibitor.
Lead Product(s): Vebreltinib
Therapeutic Area: Oncology Product Name: APL-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Apollomics Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 05, 2024
Details:
The net proceeds will be used to support clinical research and development of the Avistone pipeline, including PLB1001 (vebreltinib), a small-molecule inhibitor that targets MET tyrosine kinase activity.
Lead Product(s): Vebreltinib
Therapeutic Area: Oncology Product Name: PLB1001
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: SDIC CS Capital
Deal Size: $140.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing January 04, 2024
Details:
APL-101 (vebreltinib) is a small-molecule inhibitor that targets MET tyrosine kinase activity. It is being developed for the treatment of MET Exon 14 skip non-small cell lung cancer.
Lead Product(s): Vebreltinib
Therapeutic Area: Oncology Product Name: APL-101
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2023
Details:
APL-101 (vebreltinib) is a highly specific cMet inhibitor which is under phase 2 clinical development in non-small cell lung cancer and other solid tumors with MET dysregulations.
Lead Product(s): Vebreltinib
Therapeutic Area: Oncology Product Name: APL-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 31, 2023
Details:
Apollomics will use the financing to advance APL-101 (vebreltinib), a highly specific cMet inhibitor, in non-small cell lung cancer and other solid tumors with cMet dysregulation.
Lead Product(s): Vebreltinib
Therapeutic Area: Oncology Product Name: APL-101
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Maxpro Capital Acquisition Corp.
Deal Size: $23.6 million Upfront Cash: Undisclosed
Deal Type: Private Placement March 30, 2023